| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we demonstrated that a positive CXCL12 expression correlates significantly with a lower recurrence-free survival rate in our esophageal squamous cell carcinoma (ESCC) patient population. These results suggest that CXCL12 expression in ESCC promotes the proliferation of the tumour and has a direct impact on the recurrence rate independently of invasion or metastasis. Furthermore, the fact that both CXCL12 overexpression and CXCL12 exposure similarly promote proliferation denotes that ESCC cells expressing CXCL12 secrete this factor and cell proliferation is stimulated by the binding of CXCL12 to CXCR4 on the cell membrane, via autocrine growth.
Increased expression of both CXCL-8 and CXCR-2 correlated with tumor progression, metastasis, higher preoperative levels of proinflammatory cytokines, CRP, activation of exogenous coagulation factors, and poor prognosis in ESCC patients.
|
